Exhibit 1
Joint Filing Agreement
The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Monte Rosa Therapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D.
July 8, 2021 | ||
Versant Venture Capital VI, L.P. | ||
By: | Versant Ventures VI GP, L.P. | |
Its: | General Partner | |
By: | Versant Ventures VI GP-GP, LLC | |
Its: | General Partner | |
By: | /s/ Robin L. Praeger, Managing Director | |
Versant Ventures VI GP, L.P. | ||
By: | Versant Ventures VI GP-GP, LLC | |
Its: | General Partner | |
By: | /s/ Robin L. Praeger, Managing Director | |
Versant Ventures VI GP-GP, LLC | ||
By: | /s/ Robin L. Praeger, Managing Director | |
Versant Vantage I, L.P. | ||
By: | Versant Vantage I GP, L.P. | |
Its: | General Partner | |
By: | Versant Vantage I GP-GP, LLC | |
Its: | General Partner | |
By: | /s/ Robin L. Praeger, Managing Director | |
Versant Vantage I GP, L.P. | ||
By: | Versant Vantage I GP-GP, LLC | |
Its: | General Partner | |
By: | /s/ Robin L. Praeger, Managing Director | |
Versant Vantage I GP-GP, LLC | ||
By: | /s/ Robin L. Praeger, Managing Director |